Strategic Partnerships TAXIS develops adjunct therapies that restore the efficacy of FDA approved antibiotics, creating attractive co development or licensing opportunities for antibiotic developers seeking to extend product lifecycles and address antimicrobial resistance.

Funding Validation NIAID NIH grants and ongoing non dilutive funding validate the science and de risk early development, providing a compelling entry point for joint grant funded collaborations with larger pharma or biotech partners.

Commercial Readiness Having completed a Phase I program and generating revenue signals existing partnerships or project based engagements, which can accelerate licensing conversations or co development deals with potential buyers looking for early stage assets.

Global Reach Operating a subsidiary in Australia and ongoing leadership growth suggests opportunities for cross border licensing, regional manufacturing, and regulatory coordination with international partners.

AMR Focus A pipeline centered on efflux pump inhibitors and anti resistance agents aimed at urgent AMR threats provides a clear value proposition for pharma companies with multidrug resistant antibiotics; co development pathways could target high impact indications such as drug resistant gonorrhea.